The Rainwater Charitable Foundation

The 2027 Tauopathy Challenge Workshop will focus on how biological factors can shape cellular vulnerability, resilience, and organelle crosstalk in tau-related disease. Submit your proposal for consideration: rainwatercharitablefoundation.org/medical-resear…

🧠 Join @Being_Patient_ on May 22 for a live Brain Talks with Dr. Melissa Murray (@DrNeuroChic), a 2026 Rainwater Prize winner, on how brain bank research is advancing our understanding of tauopathies. Watch the 30-minute conversation: beingpatient.com/live-talks/

Know a scientist shaping the future of tau research? Nominations are open for the 2027 Rainwater Prize, including: 🏆 Outstanding Innovation in Neurodegenerative Research 🏆 Innovative Early‑Career Scientist Nominate by June 25: rainwatercharitablefoundation.org/medical-resear…

"As #Tau2026 comes to a close, the final panel looked ahead, exploring where the field could headed by 2030. The path forward is ambitious, but the collective momentum across the tau community continues to move the field closer to effective therapies. 🔗alz.org/tau

Momentum continued on Day 2 at #Tau2026 around advancing tau research from discovery toward clinical impact. Sessions highlighted therapeutic strategies targeting tau biology, novel delivery approaches, systems pharmacology, and ongoing clinical programs.🔗alz.org/tau

Congratulations to Dr. @marcaurelbusche, winner of the Rainwater Prize for Innovative Early‑Career Scientist, honored at #Tau2026 for uncovering an early role of tau in disrupting brain activity, pointing to new treatment paths. rainwatercharitablefoundation.org/the-rainwater-…

At #Tau2026, we honored Rainwater Prize winners Drs. Dennis Dickson (@dennis_w_d) & Melissa Murray (@DrNeuroChic) for their contributions in combining brain banking, pathology, and imaging to enhance insights into tauopathies. rainwatercharitablefoundation.org/the-rainwater-…

Day 1 at #Tau2026 highlighted advances in tau biology, genetics, neuropathology, and biomarkers. Day 2 looks ahead to translation—from drug development and clinical research to collaborative strategies driving progress toward new therapies. alz.org/tau

We’re kicking off #Tau2026, uniting researchers, clinicians, and advocates to accelerate progress in tau‑related neurodegenerative disease. We’re proud to join @alzassociation and @CurePSP in driving open science and collaboration. 🔗 Learn more: alz.org/tau

Patient voices took center stage as the FDA and other drug development decision-makers heard directly from people living with PSP. Learn about their experiences shared during @CurePSP’s Externally-Led Patient-Focused Drug Development meeting. psp.org/pfdd

Only about 25% of people with PSP, CBD, and MSA receive an accurate diagnosis, per @CurePSP. We’re proud to support efforts advancing research and awareness for these rare neurodegenerative diseases. ➡️ psp.org/iwanttolearn #HopeInAction

Dr. Timothy Miller, 2023 Rainwater Prize winner and Tau Consortium member, leads this @JAMANeuro article reporting long‑term Phase 3 and open‑label extension results in SOD1-ALS. Catch up on this example of bold, patient-focused science: jamanetwork.com/journals/jaman…

Now accepting LOIs for funding up to $750,000. The Tau Pipeline Enabling Program, jointly funded by the @alzassociation, invites researchers advancing tau‑targeted drug discovery and translation to apply. rainwatercharitablefoundation.org/the-tau-pipeli…

🎧 In this episode of The Brain Podcast, @GGKovacsBrain, a Tau Consortium investigator, highlights a potential immune-driven component of PSP and what it could mean for disease biology and future treatments. sites.libsyn.com/424160/investi…

Progress in neurodegenerative disease is built over decades. Read @washumedicine’s article on Dr. David Holtzman (@holtzman4), 2021 Rainwater Prize winner and Tau Consortium member, to learn how his work continues to shape neurodegenerative research. 🔗outlook.washu.edu/on-a-mission-t…

📺 Watch “How Do Concussions Affect the Brain?” a documentary on the first in-human PET study using [18F]OXD-2314 to track tau aggregation, shedding light on neurodegenerative diseases. We’re proud to have supported this research: tvo.org/video/how-do-c… @ConcussionCTEfn

At #ADPD2026, the spotlight shifted to tau biology, disease heterogeneity, and precision biotyping. The field showed real progress toward patient impact, from AI‑driven plasma proteomics to proof of tau lowering in PSP. Read our key takeaways: rainwatercharitablefoundation.org/insights-from-…

🎧 Listen to this episode of the Alzheimer’s Breakthrough podcast as 2026 Rainwater Prize winner Dr. Melissa Murray (@DrNeuroChic) explains how earlier detection and brain donation are advancing more targeted approaches to neurodegenerative disease. drjosh.com/episode62-alzh…

New tau biology insights are opening future therapeutic directions. In Drug Discovery Online, read more from 2026 Rainwater Prize winner Dr. Melissa Murray (@DrNeuroChic) and our Scientific Program Director Amy Rommel, Ph.D. 🔗: drugdiscoveryonline.com/doc/rethinking…

If you’re at @adpdnet 2026 in Copenhagen, we hope you’ll connect with our colleagues Amy Rommel and Glenn Harris. This meeting is an important forum for insights on biomarkers, drug development, and therapeutic strategies for neurodegenerative diseases. rainwatercharitablefoundation.org/medical-resear…